Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

DC 2.4 cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) AUTACs (1) Autophagy (1) Cytochrome P450 (1) Epigenetic Reader Domain (7) Ferroptosis (2) Glutathione Peroxidase (1) Histone Methyltransferase (2) IAP (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Molecular Glues (1) p38 MAPK (1) PROTACs (31) ROS Kinase (1)
By Research Areas:	Cancer (36)
Click Chemistry:	Azide (7)

Inhibitors & Agonists

Click Chemistry

Targets Recommended: MCHR1 (GPR24) Nuclear Factor of activated T Cells (NFAT) TREM receptor Programmed Cell Death 4 (PDCD4)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-154387

1-Isopropyltryptophan 1-IsoPT	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
1-Isopropyltryptophan (1-IsoPT) is a IDO1 inhibitor. 1-Isopropyltryptophan decreases the expression of IFN-γ stimulated ID0-1 and ID0-2 mRNA .

HY-159459

PROTAC SMARCA2/4-degrader-32	PROTACs	Cancer
PROTAC SMARCA2/4-degrader-32 (compound I-446) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-163869

PROTAC SMARCA2/4-degrader-16	PROTACs	Cancer
PROTAC SMARCA2/4-degrader-16 (compound I-337) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159458

PROTAC SMARCA2/4-degrader-7	PROTACs	Cancer
SMARCA2/4-degrader-7 (compound I-439) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159452

PROTAC SMARCA2/4-degrader-1	PROTACs	Cancer
SMARCA2/4-degrader-1 (compound I-430) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159453

PROTAC SMARCA2/4-degrader-2	PROTACs	Cancer
SMARCA2/4-degrader-2 (compound I-431) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-162741

PROTAC SMARCA2/4-degrader-33	PROTACs	Cancer
PROTAC SMARCA2/4-degrader-33 (compound I-277) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159454

PROTAC SMARCA2/4-degrader-3	PROTACs	Cancer
SMARCA2/4-degrader-3 (compound I-433) is a PROTAC *SMARCA2/4*-degrader based on VH032-NH2, with a degradation potency (DC₅₀) <100 nM in MV4-11 cells .

HY-173333

PROTAC SMARCA2/4 degrader-38	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC SMARCA2/4 degrader-38 is a degrader *SMARCA2/4* PROTAC (DC₅₀: 3.0 nM and 4.0 nM respectively). PROTAC SMARCA2/4 degrader-38 promotes the ubiquitination and degradation of SMARCA2/4. PROTAC SMARCA2/4 degrader-38 blocks the G0/G1 cell cycle and induces apoptosis. PROTAC SMARCA2/4 degrader-38 can be used in acute myeloid leukemia (AML) research. (Pink: SMARCA2/4 ligand; Blue: VHL ligand (HY-112078); Black: linker; Target Protein Ligand-Linker Conjugates (HY-173343)) .

HY-163875

PROTAC SMARCA2/4-degrader-22	PROTACs	Cancer
SMARCA2 degrader-14 (compound I-408) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-163876

PROTAC SMARCA2/4-degrader-23	PROTACs	Cancer
SMARCA2 degrader-15 (compound I-409) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-149924

CST626	PROTACs IAP	Cancer
CST626 (Compound 9) is a pan-IAP degrader PROTAC. CST626 degrades XIAP, cIAP1 and cIAP2 with *DC₅₀s of 0.7, 2.4, and 6.2 nM in MM.1S cells*, respectively .

HY-170347

PROTAC SMARCA2/4 degrader-36	PROTACs Epigenetic Reader Domain	Cancer
PROTAC SMARCA2/4 degrader-36 (Compound 29) is an effective dual degrader of *SMARCA2/4*,with *DC₅₀* values of 0.22 nM and 0.85 nM for SMARCA2 and SMARCA4, respectively. PROTAC SMARCA2/4 degrader-36 has anti-cell proliferation activity (Pink: Target Protein Ligand (HY-170354); Black: Linker (HY-W895794); Blue: E3 Ligase Ligand (HY-170353); E3 Ligase Ligand-Linker Conjugate (HY-170356)) .

HY-161930

PROTAC GPX4 degrader-3	PROTACs Ferroptosis	Cancer
PROTAC GPX4 degrader-3 is a potent PROTAC GPX4 degrader with a *DC₅₀* (24h) of 0.019 μM and an IC₅₀ of 0.024 μM in HT1080 cell .

HY-156568

SMD-3040	PROTACs Epigenetic Reader Domain	Cancer
SMD-3040 is a potent and selective SMARCA2 PROTAC degrader (DC₅₀: 12 nM; D_max: 91%). SMD-3040 can inhibit tumor cell proliferation and exhibits antitumor activity. SMD-3040 can be used in the study of tumors such as melanoma . (SMARCA2/4-ligand (HY-171765); HY-112078 VHL ligand (HY-112078))

HY-153932

NR-7h	PROTACs p38 MAPK	Cancer
NR-7h is a potent and selective p38α and p38β degrader with *DC₅₀* values of 24 nM and 27.2 nM for p38α in T47D, MB-MDA-231 cells, respectively .

HY-163874

PROTAC SMARCA2 degrader-12	PROTACs	Cancer
SMARCA2 degrader-13 (compound I-406) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-163866

PROTAC SMARCA2 degrader-14	PROTACs	Cancer
SMARCA2 degrader-3 (compound I-323) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-163867

PROTAC SMARCA2 degrader-15	PROTACs	Cancer
SMARCA2 degrader-4 (compound I-332) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-163865

PROTAC SMARCA2 degrader-13	PROTACs	Cancer
SMARCA2 degrader-2 (compound I-322) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-162747

PROTAC SMARCA2 degrader-17	PROTACs	Cancer
PROTAC SMARCA2 degrader-17 (compound I-290) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-162742

PROTAC SMARCA2 degrader-16	PROTACs	Cancer
PROTAC SMARCA2 degrader-16 (compound I-278) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159462

PROTAC SMARCA2 degrader-10	PROTACs	Cancer
PROTAC SMARCA2 degrader-10 (compound I-507) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159450

PROTAC SMARCA2 degrader-6	PROTACs	Cancer
PROTAC SMARCA2 degrader-6 (compound I-427) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-162746

PROTAC SMARCA2 degrader-9	PROTACs	Cancer
PROTAC SMARCA2 degrader-9 (compound I-285) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-156568A

SMD-3040 TFA	PROTACs Epigenetic Reader Domain	Cancer
SMD-3040 TFA is a potent and selective SMARCA2 PROTAC degrader (DC₅₀: 12 nM; D_max: 91%). SMD-3040 TFA can inhibit tumor cell proliferation and exhibits antitumor activity. SMD-3040 TFA can be used in the study of tumors such as melanoma . (SMARCA2/4-ligand (HY-171765); HY-112078 VHL ligand (HY-112078))

HY-156568B

SMD-3040 formate	PROTACs Epigenetic Reader Domain	Cancer
SMD-3040 formate is a potent and selective SMARCA2 PROTAC degrader (DC₅₀: 12 nM; D_max: 91%). SMD-3040 formate can inhibit tumor cell proliferation and exhibits antitumor activity. SMD-3040 formate can be used in the study of tumors such as melanoma . (SMARCA2/4-ligand (HY-171765); HY-112078 VHL ligand (HY-112078))

HY-170989

BRD4 degrader-5	AUTACs Epigenetic Reader Domain Autophagy	Cancer
BRD4 degrader-5 (Compound 23) is a hydrophobic tag (HyTag)-based protein degrader for BRD4 (DC₅₀ = 24.7 μM) through ER stress and autophagy-lysosome pathway. BRD4 degrader-5 inhibits the proliferation of cancer cell 4T1 with an IC₅₀ of 20.6 μM .

HY-161250

Pomalidomide-NH-PEG6-amide-C2-CPI-1612	PROTACs	Cancer
Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a *DC₅₀* of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells .

HY-138635

PROTAC BRD4 Degrader-12	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a *DC₅₀* of 0.39 nM and 0.24 nM, respectively .

HY-169264

SJYHJ-026	PROTACs	Cancer
SJYHJ-026 (compound 37) is a pregnane X receptor (PXR) PROTAC degrader with the *DC₅₀* of 86.6 nM and maximal degradation of 66.4%. SJYHJ-026 shows cell cytotoxic aganist SNU-C4 HiBiT-PXR KI cells with the IC₅₀ values of 97.4 μM (24 h) and 99.5 μM (72 h) (Blue: VHL ligand HY-125845,Black: linker HY-43048；Pink: PXR inhibitor HY-169277) .

HY-157251A

UNC8153	Histone Methyltransferase	Cancer
UNC8153 is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a K_d of 24 nM. UNC8153 reduces the cellular levels of both NSD2 protein (DC₅₀ in cell U2OS is 0.35 μM) and the H3K36me2 chromatin mark. UNC8153 contains a simple warhead that confers proteasome-dependent degradation of NSD2 .

HY-157251

UNC8153 TFA	Histone Methyltransferase	Cancer
UNC8153 TFA is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a K_d of 24 nM. UNC8153 TFA reduces the cellular levels of both NSD2 protein (DC₅₀ in cell U2OS is 0.35 μM) and the H3K36me2 chromatin mark. UNC8153 TFA contains a simple warhead that confers proteasome-dependent degradation of NSD2 .

HY-174086

PROTAC GPX4 degrader-4	Glutathione Peroxidase Ferroptosis ROS Kinase	Cancer
PROTAC GPX4 degrader-4 is a GPX4 PROTAC degrader (DC₅₀: 5.32 nM). PROTAC GPX4 degrader-4 inhibits the activity of RT4, T24, and J82 cancer cells (IC₅₀ values are 0.09, 2.97, and 7.58 μM, respectively). PROTAC GPX4 degrader-4 increases lipid ROS levels and induces ferroptosis in T24 and RT4 cells. PROTAC GPX4 degrader-4 has antitumor activity in T24 tumor-bearing BALB/c nude mouse model. PROTAC GPX4 degrader-4 can be used for bladder cancer research. (Pink: target protein ligand (HY-N0193); blue: E3 ligase ligand (HY-1035960); black: linker (HY-W013907); E3 ligase ligand + linker (HY-174087)) .

HY-158429

PROTAC CYP1B1 degrader-2	PROTACs Cytochrome P450	Cancer
PROTAC CYP1B1 degrader-2 (compound PV2) is a von Hippel-Landau (VHL) E3 ligase-based CYP1B1 degrader with the *DC₅₀* of 1.0 nM at 24 h in A549/Taxol cells. PROTAC CYP1B1 degrader-2 inhibits growth, migration, and invasion of A549/Taxol cell(Sturcture Note:(Blue: VHL ligand (HY-112078), Black: linker (HY-W007700), Pink: CYP1B1 ligand (HY-159006) .

HY-130122

MG-277	Molecular Glues PROTACs Apoptosis	Cancer
MG-277, a molecular glue degrader, effectively induces degradation of a translation termination factor based on Cereblon E3 ligand, GSPT1, with a *DC₅₀* of 1.3 nM. MG-277 potently inhibits tumor cell growth in a p53-independent manner, with IC₅₀s of 3.5 nM for RS4;11 cells and 3.4 nM for p53 mutant RS4;11/IRMI-2 cells, respectively. Anticancer activity .

Cat. No.	Product Name		Classification

HY-159459

PROTAC SMARCA2/4-degrader-32		Azide
PROTAC SMARCA2/4-degrader-32 (compound I-446) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159458

PROTAC SMARCA2/4-degrader-7		Azide
SMARCA2/4-degrader-7 (compound I-439) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159452

PROTAC SMARCA2/4-degrader-1		Azide
SMARCA2/4-degrader-1 (compound I-430) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159453

PROTAC SMARCA2/4-degrader-2		Azide
SMARCA2/4-degrader-2 (compound I-431) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the *DC₅₀*s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159454

PROTAC SMARCA2/4-degrader-3		Azide
SMARCA2/4-degrader-3 (compound I-433) is a PROTAC *SMARCA2/4*-degrader based on VH032-NH2, with a degradation potency (DC₅₀) <100 nM in MV4-11 cells .

HY-159462

PROTAC SMARCA2 degrader-10		Azide
PROTAC SMARCA2 degrader-10 (compound I-507) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159450

PROTAC SMARCA2 degrader-6		Azide
PROTAC SMARCA2 degrader-6 (compound I-427) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an *DC₅₀* <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: